| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9404585 | Surgery | 2005 | 8 Pages |
Abstract
Human pancreatic cancer cells secrete VEGF at biologically relevant high levels. AS-3 therapy normalizes plasma VEGF and decreases neoangiogenesis, thereby reducing tumor growth and metastasis and improving survival. AS-3-treated animals developed no ascites, suggesting decreased vascular permeability by reducing VEGF expression in pancreatic cancer cells.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Hubert G. MD, O. Joe MD, Rizwan PhD, Birgit Hotz, Thomas MD, Heinz J. MD, Parkash S. MD, Howard A. MD,